Amarantus Bioscience Holdings, Inc. (AMBS)

Overview

Amarantus BioScience Holdings, Inc. is a biopharmaceutical company that concentrates on the discovery and development of product candidates in various fields including neurology, psychiatry, ophthalmology, and regenerative medicine. The company strides forward with a mission to address the unmet medical needs in these areas through its innovative diagnostic and therapeutic products. Initially named Amarantus Bioscience, Inc., the company underwent a name change to Amarantus BioScience Holdings, Inc. in April 2013. Founded in 2008, Amarantus is headquartered in New York, New York. The company collaborates extensively with prestigious institutions like the U.S. Army Institute of Surgical Research and Rutgers University to enhance its research and development capabilities.

Products and Services

• Lymphocyte Proliferation (LymPro) Test

A diagnostic tool under development for Alzheimer's disease, the LymPro Test is designed to determine the ability of lymphocytes to multiply, potentially enabling early diagnosis of this neurodegenerative disorder.

• MSPrecise

An innovative DNA sequencing assay aimed at the accurate identification of patients with multiple sclerosis, MSPrecise seeks to improve diagnosis precision by analyzing the genetic material.

• Eltoprazine

This is a small molecule therapeutic candidate targeted at treating Levodopa-Induced Dyskinesia in Parkinson's disease and is also being assessed for its potential in managing attention deficit hyperactivity disorders.

• Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF)

Amarantus is developing MANF for its application in various neurodegenerative conditions, including animal models of retinitis pigmentosa and retinal artery occlusion, showcasing the company’s commitment to ophthalmological conditions.

• NuroPro

A neurodegenerative disease diagnostic platform with potential application in Parkinson’s disease, NuroPro represents Amarantus's effort in creating a broader diagnostic platform for neurodegenerative diseases.

• BC-SeraPro

An oncology diagnostic platform focused on breast cancer, BC-SeraPro is part of Amarantus's venture into the oncology space with the aim of improving the detection and management of breast cancer.

• PhenoGuard Platform

The PhenoGuard discovery platform is dedicated to neurrotrophic factor discovery, indicating Amarantus’s commitment to uncovering new pathways and treatments for neurodegenerative diseases.

• Engineered Skin Substitute (ESS)

ESS is a cell therapy-based autologous skin replacement product. Currently in mid-stage clinical development, this product is intended for the treatment of life-threatening severe burns, underlining Amarantus's involvement in regenerative medicine and its application in critical care scenarios.